Loading stock data…
BMY
$58.22-2.37 (-3.91%)
Market ClosedLast close May 1
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bristol-Myers Squibb Company in the Healthcare sector is trading at $58.22. The stock is currently 7% below its 52-week high of $62.89, remaining 14.1% above its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why BMY maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$58.22
Potential Upside
38.1%
Whystock Fair Value$80.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus25 analysts
Hold
Mean target$63.32+8.8%
Range$40.00 – $75.00
Fundamentals
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. Th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$120.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.99
Beta
Defensive asset. Lower volatility than the S&P 500.
0.27
Div Yield
Strong income play. Yield provides a meaningful total return floor.
429.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.33%
Volume
Today's trading volume
13.57M
Recent News
BMY Q1 Deep Dive: Growth Portfolio, Pipeline Milestones, and Anticipated Late-Stage Readouts
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 billion. On the other hand, the company’s full-year revenue guidance of $46.75 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.58 per share was 11.1% above analysts’ consensus estimates.
Seaport Therapeutics stock pops 17% on Nasdaq debut
The Boston-based biotech sold more stock than originally planned at $18 a share, giving it a market value of $1.1 billion
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
BMS brings the buzz around late-stage readouts amid a so-so Q1
BMS is looking to Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy to drive growth into the 2030s.